WO2003074703A1 - Nouveau facteur de transcription, adn de ce facteur et utilisation de ce facteur - Google Patents

Nouveau facteur de transcription, adn de ce facteur et utilisation de ce facteur Download PDF

Info

Publication number
WO2003074703A1
WO2003074703A1 PCT/JP2003/002648 JP0302648W WO03074703A1 WO 2003074703 A1 WO2003074703 A1 WO 2003074703A1 JP 0302648 W JP0302648 W JP 0302648W WO 03074703 A1 WO03074703 A1 WO 03074703A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
same
transcriptional factor
novel transcriptional
usable
Prior art date
Application number
PCT/JP2003/002648
Other languages
English (en)
Japanese (ja)
Inventor
Kenichi Noguchi
Takako Fuse
Akiyoshi Kunugi
Masayuki Takizawa
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2003213413A priority Critical patent/AU2003213413A1/en
Publication of WO2003074703A1 publication Critical patent/WO2003074703A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à une protéine qui est utilisable comme marqueur diagnostique pour les troubles du système nerveux et qui possède un effet inhibiteur de différenciation des neurones cholinergiques. Cette invention concerne des composés ou des sels de ces composés qui limitent (de préférence inhibent) l'activité de cette protéine ou l'expression de son gène, un polynucléotide antisens et un anticorps notamment, qui sont utilisables comme excellents promoteurs de différenciation des neurones cholinergiques dans des agents prophylactiques et/ou thérapeutiques contre les troubles du système nerveux, notamment.
PCT/JP2003/002648 2002-03-07 2003-03-06 Nouveau facteur de transcription, adn de ce facteur et utilisation de ce facteur WO2003074703A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213413A AU2003213413A1 (en) 2002-03-07 2003-03-06 Novel transcriptional factor, dna thereof and use of the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2002062524 2002-03-07
JP2002-062524 2002-03-07
JP2002-103538 2002-04-05
JP2002103538 2002-04-05
JP2002201300 2002-07-10
JP2002-201300 2002-07-10

Publications (1)

Publication Number Publication Date
WO2003074703A1 true WO2003074703A1 (fr) 2003-09-12

Family

ID=27792047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/002648 WO2003074703A1 (fr) 2002-03-07 2003-03-06 Nouveau facteur de transcription, adn de ce facteur et utilisation de ce facteur

Country Status (2)

Country Link
AU (1) AU2003213413A1 (fr)
WO (1) WO2003074703A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060928A2 (fr) * 2001-02-01 2002-08-08 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Genes et proteines medane

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060928A2 (fr) * 2001-02-01 2002-08-08 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Genes et proteines medane

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOKUBO H. ET AL.: "Identification and expression of a novel family of bHLH cDNAs related to drosophila hairy and enhancer of split", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 260, no. 2, 1999, pages 459 - 465, XP002968430 *
OHTSUKA T. ET AL.: "Roles of the basic helix-loop-helix genes Hes1 and Hes5 in expansion of neural stem cells of the developing brain", J. BIOL. CHEM., vol. 276, no. 32, 2001, pages 30467 - 30474, XP002968432 *
RYUICHIRO KAGEYAMA: "V. Saibo bunka/kotai keisei no seigyo kiko to tensha inshi, bLHL-inshi ni yoru shinkei bunka seigyo", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 45, no. 9, 2000, pages 1605 - 1611, XP002968431 *
TAKASHI OKUDA ET AL.: "Short review, ko-shinwasei choline transporter -genome joho o riyo shita cloning", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 45, no. 10, 2000, pages 1722 - 1727, XP002968433 *

Also Published As

Publication number Publication date
AU2003213413A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2004089286A3 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de la proteine kinase
WO2004096148A3 (fr) Complexe du recepteur de cytokine protecteur de tissus, dosages permettant d'identifier des composes protecteurs de tissus et utilisations associees
WO2008064255A3 (fr) Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2008060813A3 (fr) Anticorps antagonistes de haute affinité dirigés contre le récepteur alpha 1 de l'interleukine-13
EP1140840A4 (fr) Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
WO2003084473A3 (fr) Methode de traitement du cancer
HUP0003863A3 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
WO2003020287A3 (fr) Methodes de traitement de douleurs chroniques et compositions correspondantes
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
WO2005076854A3 (fr) Nouveaux composes chimiques
WO2008054534A3 (fr) Systèmes de criblage utilisant le rtp801
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
WO2008049098A3 (fr) Antagonistes d'anticorps du récepteur α1 de l'interleukine-13
WO2005089730A3 (fr) Kinase
WO2002004610A3 (fr) Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv
WO2003074703A1 (fr) Nouveau facteur de transcription, adn de ce facteur et utilisation de ce facteur
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2002012887A3 (fr) Procedes et compositions pour le diagnostic et le traitement de troubles cellulaires de tissu adipeux brun
WO2002020003A3 (fr) Utilisation d'inhibiteurs de carp dans le traitement de maladies cardiaques
WO2003074007A3 (fr) Modulateurs d'activation des leucocytes, compositions, et methodes d'utilisation
WO2003070965A8 (fr) Promoteur eaat2 et utilisations de ce promoteur
WO2006019660A3 (fr) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
WO2004035804A3 (fr) Cristaux et structures d'une proteine de liaison d'acide nucleique bacterienne
WO2001007431A3 (fr) Derives de benzothiophene
WO2004041197A3 (fr) Methodes d'inhibition de la formation de cicatrices gliales

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP